Inventor · disambiguated record
Johannes Jelle Van Der Vliet
Also filed as: VAN DER VLIET JOHANNES JELLE
7 granted patents·13 pending applications·16 citations·filing 2015–2024
80Inventor score
Top patents by PatentIndex Score
20 records- 0193US11384145B2Immunoglobulins binding human Vγ9Vδ2 T cell receptorsLAVA THERAPEUTICS N V·Filed 2021·Granted Jul 12, 2022·3 cites·21 claims
- 0285US10501540B2Immunoglobulins binding human Vγ9 Vδ2 T cell receptorsSTICHTING VUMC·Filed 2015·Granted Dec 10, 2019·6 cites·16 claims
- 0383US11591394B2Single domain antibodies targeting CD1dLAVA THERAPEUTICS N V·Filed 2019·Granted Feb 28, 2023·2 cites·8 claims
- 0481US2024425592A1Single domain antibodies targeting cd1dLAVA THERAPEUTICS N V·Filed 2024·Application pending·0 cites
- 0580US10501541B2Single domain antibodies targeting CD1dLAVA THERAPEUTICS B V·Filed 2016·Granted Dec 10, 2019·5 cites·18 claims
- 0678US12110328B2Single domain antibodies targeting CD1dLAVA THERAPEUTICS N V·Filed 2023·Granted Oct 8, 2024·0 cites·15 claims
- 0776US2023212290A1Immunoglobulins binding human vgamma9vdelta2 t cell receptorsLAVA THERAPEUTICS N V·Filed 2022·Application pending·0 cites
- 0873US12428493B2Antibodies that bind PSMA and gamma-delta T cell receptorsLAVA THERAPEUTICS N V·Filed 2024·Granted Sep 30, 2025·0 cites·8 claims
- 0966US2025099581A1Uses of gamma delta t cell activating antibodiesLAVA THERAPEUTICS N V·Filed 2024·Application pending·0 cites
- 1065US2025270660A1Assay for t cell dependent multispecific compoundsLAVA THERAPEUTICS N V·Filed 2024·Application pending·0 cites
- 1161US2024409641A1Dual acting cd1d immunoglobulin for treatment of myelodysplastic syndromesLAVA THERAPEUTICS N V·Filed 2024·Application pending·0 cites
- 1260US2025109204A1Compositions comprising antibodies that bind gamma-delta t cell receptorsLAVA THERAPEUTICS N V·Filed 2024·Application pending·0 cites
- 1360US2025230240A1Variant antibodies that bind gamma-delta t cell receptorsLAVA THERAPEUTICS N V·Filed 2024·Application pending·0 cites
- 1455US2023303694A1Antibodies that bind gamma-delta t cell receptorsLAVA THERAPEUTICS N V·Filed 2023·Application pending·0 cites
- 1555US2019263908A1Immunoglobulins binding human Vγ9Vδ2 T cell receptorsLAVA THERAPEUTICS B V·Filed 2019·Application pending·0 cites
- 1653US2024141071A1Antibodies that bind cd123 and gamma-delta t cell receptorsLAVA THERAPEUTICS N V·Filed 2022·Application pending·0 cites
- 1753US2023272110A1Antibodies that bind psma and gamma-delta t cell receptorsLAVA THERAPEUTICS N V·Filed 2021·Application pending·0 cites
- 1850US12077586B2Bispecific antibodies for use in the treatment of hematological malignanciesLAVA THERAPEUTICS N V·Filed 2019·Granted Sep 3, 2024·0 cites·13 claims
- 1950US2023036284A1TREATMENT OF CANCER COMPRISING ADMINISTRATION OF Vg9Vd2 T CELL RECEPTOR BINDING ANTIBODIESLAVA THERAPEUTICS N V·Filed 2020·Application pending·0 cites
- 2041US2022135694A1Novel cd40-binding antibodiesLAVA THERAPEUTICS B V·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Johannes Jelle Van Der Vliet files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →